Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 June 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Novel regimen appears to be safe and effective in treating esophageal cancer

Oxaliplatin, administered with protracted-infusion fluorouracil and radiation, is safe, tolerable, and seems effective against primary esophageal carcinoma, claims a team from Buffalo, New York, USA.

News image

fiogf49gjkf04

The researchers investigated the use of oxaliplatin (OXP) in combination with protracted-infusion (PI) fluorouracil (5-FU) and radiation in patients with esophageal cancer.

The findings of the trial were reported in the latest issue of the Journal of Clinical Oncology.

A total of 38 therapeutically naïve esophageal carcinoma patients were included in the study. Of these, 22 were noninvasively staged as IV and 16 were noninvasively staged as II and III.

Initial doses and schedules for cycle 1 consisted of OXP 85 mg/m2 on days 1, 15, and 29, and PI 5-FU 180 mg/m2 for 24 hours for 35 days. This was in addition to external-beam radiation therapy (XRT), 1.8 Gy in 28 fractions, starting on day 8.

Some 36 patients completed cycle 1.

Eligible patients could undergo an operation or begin cycle 2 without XRT.

Postoperative patients were eligible for cycle 2.

It was found that 29 patients started cycle 2, and 24 patients completed cycle 2.

81% of patients no longer had esophageal cancer after cycle 1.
Journal of Clinical Oncology
Stage IV patients were allowed 3 cycles in the absence of disease progression.

OXP and 5-FU increases were based on dose-limiting toxicity encountered in cohorts of 3 consecutive patients.

The team found that combined-modality therapy was well tolerated, but dose-limiting toxicity prevented OXP and 5-FU escalation.

No grade 4 hematologic toxicity was noted.

A total of eleven grade 3 and two grade 4 clinical toxicities were noted in 8 patients.

After cycle 1, 81% of patients had no cancer in the esophageal mucosa.

Some 13 patients underwent an operation with intent to resect the esophagus. Of these, 38% of the patients exhibited pathologic complete responses.

Dr Nikhil I. Khushalani, of the Roswell Park Cancer Institute, Buffalo, said on behalf of fellow authors, "OXP 85 mg/m2 on days 1, 15, and 29, administered with PI 5-FU and XRT is safe, tolerable, and seems effective against primary esophageal carcinoma."

"The role of OXP in multimodality regimens against esophageal carcinoma deserves further evaluation," it was concluded.

J Clin Oncol 2002; 20(12): 2844-50
19 June 2002

Go to top of page Email this page Email this page to a colleague

 31 May 2018 
Diagnostic for NAFLD  
 31 May 2018 
Bile acids and the risks for hepatotoxicity
 31 May 2018 
Rectal cancer female sexuality score
 30 May 2018 
Fungal dysbiosis in cirrhosis
 30 May 2018 
Placebo rates in ulcerative colitis trials
 30 May 2018 
Follow-up testing and colorectal cancer mortality
 29 May 2018 
Organ transplantation donors
 29 May 2018 
Novel therapies for IBD
 29 May 2018 
Helicobacter pylori infection to stomach cancer
 28 May 2018 
Mesalazine in ulcerative colitis
 28 May 2018 
Technology and management of digestive diseases
 28 May 2018 
Therapeutic strategies for HCV
 25 May 2018 
Post‐operative complications in elderly IBD
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Colorectal cancer–specific mortality
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Chronic Hep B
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
European guidelines on pancreatic cystic neoplasms

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us